JP2019534890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534890A5 JP2019534890A5 JP2019520628A JP2019520628A JP2019534890A5 JP 2019534890 A5 JP2019534890 A5 JP 2019534890A5 JP 2019520628 A JP2019520628 A JP 2019520628A JP 2019520628 A JP2019520628 A JP 2019520628A JP 2019534890 A5 JP2019534890 A5 JP 2019534890A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition
- nanoparticles
- composition according
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406542P | 2016-10-11 | 2016-10-11 | |
| US62/406,542 | 2016-10-11 | ||
| PCT/US2017/056188 WO2018071572A1 (en) | 2016-10-11 | 2017-10-11 | Nanoparticles functionalized with gene editing tools and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534890A JP2019534890A (ja) | 2019-12-05 |
| JP2019534890A5 true JP2019534890A5 (https=) | 2020-10-15 |
Family
ID=61905970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520628A Pending JP2019534890A (ja) | 2016-10-11 | 2017-10-11 | 遺伝子編集ツールによって機能化されたナノ粒子および関連する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190233820A1 (https=) |
| EP (1) | EP3525831A4 (https=) |
| JP (1) | JP2019534890A (https=) |
| CA (1) | CA3039924A1 (https=) |
| WO (1) | WO2018071572A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| CN108026526B (zh) | 2015-06-09 | 2023-05-12 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| KR20220146437A (ko) * | 2020-01-10 | 2022-11-01 | 안드라닉 앤드류 아프리키안 | 목적 유전자의 발현 및/또는 신호전달 경로의 조절을 위한 나노입자 |
| US20220162601A1 (en) * | 2020-11-23 | 2022-05-26 | Recursion Pharmaceuticals, Inc. | High throughput gene editing system and method |
| WO2022210822A1 (ja) * | 2021-04-02 | 2022-10-06 | キヤノン株式会社 | 試薬、及びそれを用いた標的核酸の検出方法 |
| JP2022158921A (ja) * | 2021-04-02 | 2022-10-17 | キヤノン株式会社 | 試薬、及びそれを用いた標的核酸の検出方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10022457B2 (en) * | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| TWI576432B (zh) * | 2009-04-07 | 2017-04-01 | 陶氏農業科學公司 | 序列特異性核酸酶之奈米粒子媒介式遞送技術 |
| CA2938661A1 (en) * | 2011-10-21 | 2013-04-25 | Stemgenics, Inc | Functionalized nanoparticles for intracellular delivery of biologically active molecules |
| PL3360964T3 (pl) * | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| RU2716420C2 (ru) * | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени |
| JP6455912B2 (ja) * | 2014-03-24 | 2019-01-23 | 国立研究開発法人産業技術総合研究所 | 人工ヌクレアーゼの細胞への導入方法 |
| WO2016028682A1 (en) * | 2014-08-17 | 2016-02-25 | The Broad Institute Inc. | Genome editing using cas9 nickases |
| WO2016094874A1 (en) * | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
| WO2016124765A1 (en) * | 2015-02-06 | 2016-08-11 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| WO2016197133A1 (en) * | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics, Inc. | Delivering crispr therapeutics with lipid nanoparticles |
| US20180237800A1 (en) * | 2015-09-21 | 2018-08-23 | The Regents Of The University Of California | Compositions and methods for target nucleic acid modification |
-
2017
- 2017-10-11 CA CA3039924A patent/CA3039924A1/en active Pending
- 2017-10-11 WO PCT/US2017/056188 patent/WO2018071572A1/en not_active Ceased
- 2017-10-11 US US16/341,025 patent/US20190233820A1/en not_active Abandoned
- 2017-10-11 EP EP17859677.1A patent/EP3525831A4/en active Pending
- 2017-10-11 JP JP2019520628A patent/JP2019534890A/ja active Pending
-
2024
- 2024-10-04 US US18/906,758 patent/US20250101425A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534890A5 (https=) | ||
| Chen et al. | Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR–Cas9 ribonucleoprotein | |
| Ryu et al. | Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy | |
| US11268092B2 (en) | Structure-engineered guide RNA | |
| CN109689677B (zh) | 用于基因组编辑分子的细胞内递送的肽和纳米颗粒 | |
| Zintchenko et al. | Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity | |
| US20200347387A1 (en) | Compositions and methods for target nucleic acid modification | |
| US11213594B2 (en) | Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids | |
| JP7568511B2 (ja) | カチオン性ポリマーおよびその生体分子送達のための使用 | |
| WO2019232069A1 (en) | Cell therapy | |
| JP2020510410A5 (https=) | ||
| Nelles et al. | Applications of Cas9 as an RNA‐programmed RNA‐binding protein | |
| EP3234192A1 (en) | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing | |
| US20250101425A1 (en) | Nanoparticles functionalized with gene editing tools and related methods | |
| AU2020263474B2 (en) | Cationic polymer with alkyl side chains | |
| JP7805789B2 (ja) | 生体分子送達のための複数の機能化側鎖を含むポリマー | |
| US20230096378A1 (en) | Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition | |
| US20230147779A1 (en) | Polymer with cationic and hydrophobic side chains | |
| AU2022284287A1 (en) | Rna-guided casω nucleases and uses thereof in diagnostics and therapy | |
| Yu et al. | Latest progress in the study of nanoparticle-based delivery of the CRISPR/Cas9 system | |
| Eksi et al. | Nanodelivery in gene therapy: unlocking the potential for precision medicine | |
| JP2024525141A (ja) | ポリアミン基およびポリアルキレンオキシド基を有する側鎖を含む生分解性ポリマー | |
| Ali et al. | Overview of delivery of CRISPR/Cas systems, its types, and role in genome editing and immunotherapy | |
| Schallon et al. | DNA melting temperature assay for assessing the stability of DNA polyplexes intended for nonviral gene delivery | |
| Gottimukkala et al. | CRISPR-AuNP: physicochemical optimization of a gold nanoparticle platform for cost-effective and modular non-viral gene editing in HSPCs |